Acelyrin: Potential Buyout Led By Concentra Biosciences
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...
DelveInsight Business Research, LLP: Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...